We are live on
!
Find out more
KA
Kearns & Associates Portfolio holdings
AUM
$214M
1-Year Est. Return
23.8%
This Fund
S&P 500
This Quarter
Est. Return
+1.28%
1 Year Est. Return
+23.8%
3 Year Est. Return
+69.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$155M
AUM Growth
+$3.07M
(+2%)
Cap. Flow
+$1.55M
Cap. Flow
% of AUM
1%
Top 10 Holdings %
Top 10 Hldgs %
88.41%
Holding
44
New
1
Increased
7
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Morningstar Growth ETF
VUG
|
+$622K |
| 2 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$472K |
| 3 |
Royalty Pharma
RPRX
|
+$469K |
| 4 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$167K |
| 5 |
Schwab International Equity ETF
SCHF
|
+$79.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$219K |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$79.6K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 4.71% |
| 2 | Financials | 3.81% |
| 3 | Communication Services | 1.4% |
| 4 | Healthcare | 1.24% |
| 5 | Consumer Discretionary | 0.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Wells Fargo
WFC
$261B
| $492K | 0.32% |
7,000
| – | – |
|
27
JPMorgan Chase
JPM
$935B
| $470K | 0.3% |
1,960
| – | – |
|
28
Vanguard Real Estate ETF
VNQ
$39.2B
| $452K | 0.29% |
5,069
+14
| +0.3% | +$1.32K |
|
|
29
Royalty Pharma
RPRX
$25.9B
| $451K | 0.29% |
+17,685
| New | +$469K |
|
30
Capital One
COF
$128B
| $387K | 0.25% |
2,170
| – | – |
|
31
Herbalife
HLF
$1.29B
| $381K | 0.25% |
56,900
| – | – |
|
32
Equinix
EQIX
$101B
| $363K | 0.23% |
385
| – | – |
|
33
iShares Core S&P 500 ETF
IVV
$878B
| $356K | 0.23% |
605
| – | – |
|
34
Johnson Controls International
JCI
$88.8B
| $355K | 0.23% |
4,500
| – | – |
|
35
Stryker
SYK
$125B
| $346K | 0.22% |
960
| – | – |
|
36
Walt Disney
DIS
$167B
| $336K | 0.22% |
3,020
| – | – |
|
37
Baker Hughes
BKR
$60B
| $308K | 0.2% |
7,500
| – | – |
|
38
Qualcomm
QCOM
$155B
| $293K | 0.19% |
1,905
| – | – |
|
39
Lowe's Companies
LOW
$117B
| $247K | 0.16% |
1,000
| – | – |
|
40
ConocoPhillips
COP
$147B
| $246K | 0.16% |
2,482
| – | – |
|
41
Danaher
DHR
$137B
| $209K | 0.14% |
910
| – | – |
|
42
Union Pacific
UNP
$174B
| $205K | 0.13% |
900
| – | – |
|
43
Johnson & Johnson
JNJ
$618B
| $202K | 0.13% |
1,400
| – | – |
|
|
44
UnitedHealth
UNH
$376B
| – | – |
-375
| Closed | -$219K |
|
Similar funds
TSS
CMBA
RC
VCM
IH
IAM
CCM
VFG
Kearns & Associates's Q4 2024 Portfolio in Review
As of Q4 2024, Kearns & Associates held 44 positions worth $155M, up 2% from $152M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Trading was light in Q4 2024: portfolio turnover was 4.5%. Kearns & Associates opened 1 new position and exited 1, leaving the 44-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 4.7% of assets, up from 4.6% a quarter earlier, followed by Financials and Communication Services.
- Kearns & Associates's largest Q4 2024 buy was Royalty Pharma: 17,685 shares worth $451K.
- Kearns & Associates added most to Vanguard Morningstar Growth ETF in Q4 2024, an estimated $622K increase.
- Kearns & Associates's biggest Q4 2024 reduction was Vanguard S&P 500 ETF, cutting an estimated $79.6K.
- Kearns & Associates fully exited UnitedHealth in Q4 2024, selling an estimated $219K.
- Kearns & Associates's ten largest holdings make up 88% of its $155M portfolio in Q4 2024.
- Kearns & Associates opened 1 new position and closed 1 in Q4 2024.
- Kearns & Associates's portfolio value rose 2% quarter-over-quarter to $155M.
Based on Kearns & Associates's 13F filing for Q4 2024, filed 23 Jan 2025.